FGFR, an important molecule in the signaling pathway, is responsible for the regulation of cell proliferation and angiogenesis, and the most common types of variants in CCA are FGFR2 fusions and mutations, which makes drugs targeting FGFR variants highly valuable in the treatment of CCA [105]. Here, FGFR2 is linked to cholangiocarcinoma.